Abstract: Breast cancer is the most frequently diagnosed and the second cause of cancer deaths among women. Several genes are found to be significantly responsible for developing breast cancer. When healthy, these genes act as tumor suppressors by producing a protein that prevents cells from growing uncontrollably. But with mutations and other disorders in these genes, cells can grow quickly and tumors may form. In previous research it has been shown that higher risk of developing breast cancer is associated with having a number of gene mutation, but it is not clear how genetic factors affect the survival pattern in breast cancer patients in the presence of clinical and other relevant factors. In this paper, we consider the joint effect of a number of important genes and relevant clinical factors to study the survival pattern of breast cancer patients using data from The Cancer Genome Atlas (TCGA) project. Among the clinical variables, increasing age, premenopausal status, prior history of cancer and neoplasm status with tumor, Black or African American race and stage IIIA have significantly higher risk of failure (death) from breast cancer. We found significant difference in survival time between altered and non-altered cases in four genes FOXA1, MLH1, RAD50, and RAD51C while considered genetic factors only. After controlling for clinical factors, patients with three mutated genes RAD50, PTEN, and MAP3K1 had higher relative risk of failure from breast cancer.
Introduction
Breast cancer which starts in the tissues of the breast is the most frequently diagnosed cancer and the second cause of cancer deaths in women. Invasive Ductal Carcinoma (IDC) is the most common type of breast cancer and it comprises about 70% to 80% of all breast cancer (National Breast Cancer, 1991) . About 10% of all cases of advanced breast cancer are Invasive Lobular Carcinoma (ILC). In 2017, an estimated 255,180 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S, along with 63,410 new cases of non-invasive breast cancer (Breastcancer.org, 1999) . Men can also have breast cancer, although breast cancer in male is not as prevalent as in women. About 2,470 new cases of invasive breast cancer are expected to be diagnosed in men in (Breastcancer.org, 1999 .
Prognostic factors of breast cancer constitute both clinical and genetic factors as found in the literature. A number of studies (Faradmal et al., 2012; Abadi et al., 2014; Bilal et al., 2013) , investigated the role of clinically associated factors such as, age at menopause, age at diagnosis, stage of the disease, tumor size, histological grade, type of therapy received (hormone therapy, radiotherapy, or chemotherapy), and family history on patient's survival. Similarly a number of studies (Martin and Weber, 2000; Apostolou and Fostira, 2013; Ciriello et al., 2015) , addressed association of genes and their mutations with occurrences of breast cancer. In order to investigate the joint role of clinical and genetic factors on the breast cancer patient's survival we abstracted survival, clinical, and gene expression data from TCGA separately and combined them.
Gene expression levels can provide how information from a gene is used in the composition of a functional gene product (Wikipedia, 2001a) . Products are often proteins, but in non-protein coding genes such as transfer RNA (tRNA) or small nuclear RNA (snRNA) genes, the product is a functional RNA. Expressions are quantified to study cellular changes in response to external changes or stimuli and to study differences between healthy and diseased states.
RNA-Seq (RNA Sequencing), also called whole transcriptome shotgun sequencing (WTSS), uses next-generation sequencing (NGS) to reveal the presence and quantity of RNA in a biological sample at a given time (Wikipedia, 2001b) . It is generally used to compare differential gene expressions between two or conditions, such as treated vs non-treated, wild-type versus mutant, and to find out which genes are up-or down-regulated in each condition. We considered the RNA-Seq expression data for all the patients as genetic factors from TCGA database.
In previous research it has been shown that higher risk of developing both invasive breast cancer is associated with having a number of gene mutation. One study based TCGA data, (TCGA, 2012) showed mutations in number of genes are associated with many subtypes of breast cancer. Another study (Giovanni et al., 2015) , profiled both IDC and ILC using TCGA data and found association between mutations in a number of genes and development of IDC and ILC. Although there was attempt to include both clinical factors and genetic profiling (Haoming et al., 2015) , in identifying the risk of developing breast cancer, it is not clear how genetic factors affect the relative risk of developing breast cancer and patients' survival in the presence of clinical and other relevant factors. In this paper, we consider the joint effect of a number of important genes and other relevant factors to study the survival pattern of breast cancer patients using data from The Cancer Genome Atlas (TCGA) project.
Data and Variables

Data Source
The RNA-Seq data for this study has been retrieved from the Open Access data tier of TCGA genome data analysis center (http://gdac.broadinstitute.org/) which is an interactive data system for researchers to search, download, upload, and analyze cancer genomic data, including breast cancer data (TCGA, 2012). Since we wanted to explore a particular point of interest, survival analysis of breast cancer on clinical and genetic factors, we retrieved the clinical data (Breast Invasive Carcinoma TCGA, Provisional) from cBioPortal which is an exploratory analysis tool for exploring large-scale cancer genomic data sets.
The Breast Cancer Dataset
The clinical data contains 1105 cases and 118 variables whereas the RNA-Seq data with gene expression information has 1100 cases with 17675 gene information. We considered 9 clinical factors and 25 genes (Antoniou and Easton, 2006; Easton, 1999) , among all the available information, which were found to be stated as significant factors (Cerami et al., 2012; Yang et al., 2007) in the breast cancer literature. A single outcome, i.e breast cancer specific survival is investigated for the survival analysis. Since we need the same number of patients in both clinical and RNA-Seq data, we matched the patient ID in both data and found 1100 patients that fulfill the matching criterion. Two hundred and ninety one patient records with unknown clinical information have been excluded from downstream analysis for the remaining 809 cases.
Among patient information gender, menopause status (at time of diagnosis), race, tumor status (at time of last contact or death), vital status (at date of last contact) are chosen (Helmrich et al., 1983) . Histologic subtype and age at initial diagnosis are selected from pathologic information and stage variable comes from (AJCC) staging manual (Giuliano et al., 2017) . In order to create the survival object (response variable), information were collected on number of days from the date of initial pathologic diagnosis to date of death and date of last contact for patients who were initially diagnosed as breast cancer carrier between year 1988 and 2013.
We identified normal and tumor samples by using the TCGA barcode. The two digits at position 14-15 of the barcode indicates the sample type. Tumor type ranges from 01-09, normal type from 10-19, and control samples from 20-29. In gene expression analysis, a common approach to differentiate a gene's expression between two conditions is to use a threshold value for what is called fold change(FC) (Tutorial, 2015) . Simply considering FC as a measure of differential expression may not be valid in this case. Thus we scale the gene expression value by a standardized transformation and calculate z-score for each expression value.
For gene expression data, the standard rule is to compute the relative expression of an individual gene and tumor to the gene's expression distribution in a reference population. The reference population is either all tumors that are diploid (containing two complete sets of chromosomes, one from each parent) for the gene in question or when available, normal adjacent tissue. The returned value indicates the number of standard deviations away from the mean of expression in the reference population (z-score). This measure is useful to determine whether a gene is up-or down-regulated relative to the normal samples or all other tumor samples. In this study, we considered those genes with z > ±1.96 (roughly p = 0.05 or 2 SD away) to be differentially expressed. To obtain z-scores for the RNA-Seq data we use following formula:
Expression for gene X in tumor Y − Mean expression for gene X in normal Standard deviation of expression for gene X in normal
We used the z-score values to define which samples are altered and which do not change. The numbers for altered and not altered refer to the number of samples with gene expression higher/lower than a specific threshold such as z-score of 2. That is we can define altered versus not altered as follows:
The dependent variable for this study is overall survival time after the diseases has been initially diagnosed. To perform survival analysis we need the following three main constructs:
• time: the time till an event happens
• status: indicates which patients have to be kept for the analysis • event: indicates which patients have death after initial pathological diagnosis (IPD).
In addition to these three constructs, we also define a censoring indicator as follows:
Censoring indicator = 1; if a patient is alive at time of survey 0; otherwise.
The time variable is defined as the number of days to death after IPD and number of days to last contact after IPD (for censored cased).
For our analysis data, the median survival time of the breast cancer patients is 3472 days after IPD with 87.38% censoring in the data.
Methods
To determine the moderated effect of important clinical factors of breast cancer on patient's survival with information on gene expression for a number of significant genes, we fit the standard Cox Proportional Hazards (Cox, 1972) model for univariate analysis and the penalized Cox PH model (Heinze and Schemper, 2001 ) for combined analysis. Important clinical and demographic factors associated to the disease are selected consulting the literature on breast cancer. We also search the literature to narrow down a short list of genes found so far to be linked to Invasive Ductal Carcinoma (IDC). Twenty five genes that are found to be directly associated with IDC are selected. For each gene its expression value is converted to z-score and based on a threshold value, as discussed in section 2, each gene is labeled as altered versus not altered. To further narrow down the number of genes that will be added to the combined Cox PH model, we considered both univariate and multivariate analysis for each gene alone, and with rest of the genes excluding the gene under investigation respectively. Survival functions for the altered and not altered groups are compared under both scenarios. If the survival functions are statistically significantly different among the altered www.jBiomedAnalytics.org versus not altered groups for a particular gene, then it is added to the combined model for further analysis. An ultra-brief overview of survival analysis is presented as follows.
A subject or patient's survival status can be estimated by calculating what is called the Product-limit (PL) estimator (Kaplan and Meier, 1958) of the survival function defined aŝ
is the estimated survival function at time t j , d j is the number of events occurred at t j , and n j is the number of subjects available at t j . After estimating survival functions, we can compare these among two or more groups using Logrank test (Mantel, 1966) . For instance, we implemented Log-rank test to identify the most important genes whose status of being altered or not are associated significantly with patient survival. The null hypothesis for this test can be formulated as follows:
H 0 : Survival function for patients with altered gene is the same as that for patients with non-altered gene H A : Survival functions are not equal for these two groups Symbolically we can write,
If the survival function is significantly different among altered and not altered groups for a specific gene, we select and include it to the combined Cox PH model. This approach is useful in learning the effect of this specific gene under investigation on patient's survival in the presence of clinical factor and other selected genes.
The semi-parametric Cox PH model (Cox, 1972) is commonly used regression model for time-to-event response variable. Cox PH model fits the hazard of having the event under consideration (IDC, in this case), using an unspecified baseline hazard function and an exponentiated form of a set of covariates. Mathematically the model can be written as follows:
where h(t|x) is the conditional hazard function for a subject i with covariate information given as the vector x i , h 0 (t) is the baseline hazard function that is independent of covariate information, and β is the vector of regression coefficients corresponding to the covariates. In order to determine if a particular predictor has any effect on patient's survival, we calculate what is called the hazard ratio (HR) based on the estimated regression coefficients from the fitted Cox PH model. The hazard ratio for a covariate x r can be expressed by the following simple formula e βr . Thus hazard ratio for any covariate can be obtained by exponentiating the corresponding regression coefficient.
Results and Discussions
As mentioned in section 2, we considered nine clinical factors including age and twenty five genes in our analysis. Except age, rest of the clinical factors are categorical. Patient's age distribution is shown in Figure 1 years. Note that, there are 2 missing observations in age variable which is indicated by NA in the graph.
We present the descriptive summary statistics of the other clinical predictors in Table 1 . 
Survival Pattern for Gene Expression Data
Using product limit (PL) estimator, we obtained survival curves for each of the twenty-five genes. The survival curves compare survival patterns between two groups: altered and nonaltered. Here we included the results from the genes those have significant difference in their survival pattern. The p-value indicates the significant role of the gene in differential survival pattern when its expression level is considered as altered versus not altered.
Note that, in Figure 2 , the red line in the graphs indicates non altered and the black line indicates for altered group. We see that patients who have altered MLH1, FOXA1 and RAD51C genes are less likely to survive compared to the non-altered groups among these genes. However, p-value for RAD50 gene indicates that patients with alteration of this gene have a better survival than non-altered group.
Fitting Penalized Cox PH Model
To select the most significant genes for the final analysis we used penalized Cox PH model (Heinze and Schemper, 2001 ) by penalizing all twenty-five genes keeping the clinical factors unpenalized. We considered a range of values for the shrinkage or penalty parameter λ from 3 to 20. Based on the non zero regression coefficients, we selected 13 genes from the RNASeq data for the final model. Table 2 and Table 3 show the estimated coefficients (β), corresponding hazard ratios (HR), z, and p-values from these analyses considering λ = 20 and λ = 15 respectively.
While the shrinkage parameter value λ is held at a higher value of 20, we see from Table 2 that the coefficients for genes BRCA1, GATA3, PIK3CA, RAD50, and RAD51C were not shrunk toward zero. This implies that these five genes are important while controlling for the clinical factors, although only RAD50 is statistically significant at the 10% level of significance. Table 3 presents the results when we reduce the shrinkage parameter value λ from 20 to 15. We see from that the coefficients for four additional genes BARD1, MLH1, MSH2, and PTEN were not shrunk toward zero. This implies that these nine genes are important while controlling for the clinical factors, again only RAD50 is statistically significant at the 10% level of significance. In addition it is to be noted that BRCA1, GATA3, PIK3CA, RAD50, www.jBiomedAnalytics.org and RAD51C are retained by both penalized models. In our final combined analysis, we considered the genes that are retained with λ = 10 in order to keep higher number of influential genes. Finally we identified important genes for breast cancer controlling for the clinical factors using the regular Cox model.
Modeling Hazard on the Combined Model with both Clinical and RNA-Seq Data
We included seven out of nine clinical factors identified from the separate analysis on clinical factors and thirteen out of twenty five genes identified using penalized Cox model to our combined analysis. Estimated regression coefficients are presented in Table 4 along with hazard ratios (HR), z-values, and corresponding p-values. Here, n= 808, number of events(deaths)= 102 after deleting 292 observations due to missingness. Note that, Black or African American group has been used as the reference category for race variable. Similarly, the references for menopause status, stage, prior history, and neoplasm status are pre-menopausal group, stage IIIA, patients with prior occurrence of breast cancer, and with tumor respectively. Also, the altered group has been considered as the reference for all the selected genes. From Table 4 , we see that there is 1.05 times increase in the expected hazard relative to a one year increase in age. The patients who belong to White race category have 2.36 times less failure rate compared to the African Americans or Black patients and have significant effect on death from breast cancer. Others have 1.56 times more failure rate than African Americans but does not have significant effect on overall survival status.
In the case of prior history, we can see that patients who have history of prior disease occurrences are 2.74 times more likely to die compared to a patient with no prior history. This factor shows significant effect on death from breast cancer.
www.jBiomedAnalytics.org Tumor status is a vital factor for death from any cancer. From Table 4 , we can see that patients with tumor have 7.97 times more failure rate compared to a patient with no neoplasm tumor and is highly significant on overall survival.
Stage level plays an important role on death from breast cancer. From the Table 4 , it can be seen that patients who belong to Stage I and IIB have respectively 1.49 and 1.10 times less failure rate compared to a patient from Stage IIIA and these two stage levels have significant effect on death. Moreover, patients who belong to stage IA are 0.68 times less likely to die compared to the patient at stage IIIA and is statistically significant.
After controlling for the clinical factors, only MAP3K1, PTEN, and RAD50 show significant influence on the survival of breast cancer. The patients with non-altered MAP3K1 and RAD50 genes have respectively 3.02 and 2.02 times more rates of death compared to the altered carriers. Whereas, patients with non-altered PTEN have 2.30 times less rate of death than the altered carriers.
Conclusion
In this study, a survival analysis of 1100 breast cancer cases revealed that a number of gene mutations independently predicts breast cancer survival, whereas some of them were not significantly associated with overall higher survival.
From product limit (also known as Kaplan Meier) analysis, we found significant difference in survival times between altered and non-altered cases in four genes namely, FOXA1, MLH1, RAD50, and RAD51C. After controlling for clinical factors, three RAD50, PTEN, and MAP3K1 mutated patients had higher relative risk of failure from breast cancer.
Furthermore, using combined data for both clinical variables and gene expression from the same 1100 breast cancer cases, we identified the most significant factors to predict overall survival. Similar to the results of univariate analysis from Kaplan-Meier estimates, RAD50 showed significant association with survival from breast cancer. In addition, MAP3K1 and PTEN genes had been identified as significant predictors for survival where the altered carriers of PTEN had worse survival or higher risk of death than the non-altered cases after controlling for the clinical variables. The patients with altered MAP3K1 had better survival than the non-altered carriers. Our results on the influentials genes for development of breast cancer after controlling for clinical factors conform with findings from previous studies (TCGA, 2012; Giovanni et al., 2015) .
While we conducted the analysis on clinical variables, controlling for the genetic factors, patients with increasing age, pre-menopausal status, prior history of cancer and neoplasm status with tumor have significantly higher risk of failure (death) from breast cancer. Also, patients who belong to White race group have lower rate of death compared to Black or African American. Patients at stage I, IA and IIB have significantly better survival than patients from at IIIA.
Although, to our knowledge, the patient cohort (1105 cases) includes nearly all important factors (both genomic and clinical) combined, it is possible that some clinical and genetics factors are not recorded and our findings should be further validated with integrated platforms. Another shortcoming of this research is that we limited to twenty five genes based on the literature search on breast cancer. An objective gene selection from all available genes in the database is left as future research.
Missingness is a major drawback in biomedical studies. In particular, often times missing data fail to observe and include all important information about the patients. We completely ignored the missingness of the covariates and excluded from all downstream analysis. Taking into account the covariates for which information was incomplete might give us more accurate results.
The results should be interpreted with caution as we have not cross-validated the findings across other platforms, such as genomic DNA copy number arrays, DNA methylation, or protein arrays (TCGA, 2012) . Nevertheless, the discovery of combined effect of important clinical and genomic predictors on patient survival in breast cancer may have important implications in identifying influential genes controlling for clinical factors and vice versa.
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